Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma

Recruiting now

Conditions studied: Metastatic Urothelial Carcinoma

In brief

The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.

Key facts

Study ID

NCT07339878

Run by

University Hospital, Strasbourg, France

People needed

50

Starts

2025-04-20

Expected to finish

2026-04-20

Last updated by the study team

2026-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients over 18 years of age
• Metastatic urothelial carcinoma
• Treated with first-line metastatic therapy since October 2024

You may not qualify if…

• Patient who expressed opposition to participating in the study

Where it is running

• Service Oncologie Médicale - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.